PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.38%
Net income growth under 50% of GNPX's 65.55%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
3.11%
D&A growth of 3.11% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-10.59%
Negative yoy deferred tax while GNPX stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-5.75%
Both cut yoy SBC, with GNPX at -88.17%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
224.19%
Well above GNPX's 405.24% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
351.62%
AP growth of 351.62% while GNPX is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-1034.42%
Negative yoy usage while GNPX is 4739.48%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-5.75%
Negative yoy while GNPX is 504.93%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.47%
Some CFO growth while GNPX is negative at -66.25%. John Neff would note a short-term liquidity lead over the competitor.
90.96%
Some CapEx rise while GNPX is negative at -1573.88%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.96%
We have mild expansions while GNPX is negative at -1573.88%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-1.15%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-84.36%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.